• Explore /
  • Poster
  • / A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).

A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).

Abstract Poster

Authors

null

Rahul Raj Aggarwal

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Rahul Raj Aggarwal , Joshi J. Alumkal , Russell Zelig Szmulewitz , Celestia S. Higano , Alan Haruo Bryce , Angela Lopez-Gitlitz , Sharon Anne McCarthy , Branko Miladinovic , Kelly McQuarrie , Shibu Thomas , Eric Jay Small

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT01790126

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 320)

Abstract #

320

Poster Bd #

M4

Abstract Disclosures

Similar Posters

First Author: Emmanuel S. Antonarakis

First Author: Rana R. McKay

Poster

2024 ASCO Genitourinary Cancers Symposium

Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.

Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.

First Author: Zin Myint

First Author: Nicholas George Nickols